Booster Dose of COVID Vaccine may Provide Better Immunity in Individuals at Risk

COVID-19 booster shots ready for inoculation among all the immunocompromised individuals, amidst surging infections from the Delta variant as per The US Centers for Disease Control and Prevention (CDC).

Immunocompromised patients represent 3 % of US adults that include patients with organ transplant, cancer treatments, rheumatologic conditions, HIV and lekaemia. As these individuals have fragile immune systems, they are more vulnerable to severe COVID-19 outcomes.

Post-COVID Linked to More Than 200 Symptoms
Long-COVID or Post-COVID is the clinical complication that lasts weeks or months after recovering from COVID-19. A new study found that it might be associated with more than 200 symptoms and can last for beyond seven months.

‘COVID-19 booster shots may provide better immunity among all the immunocompromised individuals, amidst surging infections from the Delta variant. ’

Tweet it Now

This may also enable the higher rate viral spread to others as reported by the Washington Post. Currently the advisory panel awaits the full approval of the US Food and Drug Administration (FDA).

The Expanded Access

At present the authorized ones include a two-dose regimen of the Pfizer-BioNTech and Moderna vaccines, or a single dose of the Johnson & Johnson shot. Hence this result in exploring a programme (expanded access or compassionate use) that allows sick people to get unapproved drugs by the CDC until FDA grants the permission.

Japanese Food Natto Might Help in COVID-19 Treatment
Natto, the traditional Japanese food, contains substances that can serve as potential antiviral drugs against SARS-CoV-2. Researchers suggest the potential antiviral activities of natto extracts along with the other health benefits of this food.

This program generally allows the patients with a serious disease or condition to get access to investigational new drug/product that is not FDA-approved. E.g., Coronavirus vaccines.

"FDA, CDC, and NIH (National Institutes of Health) are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary," says the report statement.

COVID-19 Effects in People With Learning Disabilities
As COVID-19 increases the risk of hospital admission and death in people with learning disabilities, they should be given priority in COVID-19 testing and vaccination

The experts believe that the booster dose in immunocompromised people may enhance the antibody responses against the disease. The third dose of the Pfizer-BioNTech coronavirus vaccine to severely immunocompromised adults has been now rolled out even by Israel.

France is also offering booster shots to immunocompromised individuals. Meanwhile Pfizer COVID-19 vaccine dose preparation has been undertaken by a staff member at the Melbourne Showgrounds in Australia.

Pfizer COVID Vaccine Approved For Australians Aged 12-15
Pfizer's COVID-19 vaccine has been approved for children aged 12 to 15 years. It makes it the first coronavirus vaccine approved for individuals younger than 16 in Australia.

Merits Of Booster COVID-19 Shot

The third COVID-19 vaccine dose of – either Pfizer’s, Moderna’s or Johnson & Johnson’s showed boosted antibody levels in certain immunocompromised organ transplant recipients as per Annals of Internal Medicine.
In a study of 30 booster dose vaccinated patients, 12 patients (6 had no antibodies and 6 had low levels prior) had developed high levels of antibodies, 2 had low levels and 16 still didn’t develop any antibodies.
Other study in the New England Journal of Medicine showed that 67 out of 99 organ transplant recipients vaccinated with Pfizer’s jab had developed antibodies after a third dose.
Lancet reported detectable antibodies after two doses of Pfizer’s COVID-19 vaccine in more than 75% of blood, or hematopoietic, stem cell transplant recipients.
Among 12 dialysis patients with no initial antibody levels after two vaccine doses, an extra shot mounted the antibody response in almost half of them as per a preliminary study posted at medRxiv.org.
Almost 42%, that is, 5 out of 12 antibody-negative patients had good response to third vaccine as per Nephrology Dialysis Transplantation.

As the data on third dose continues to prove its efficacy, it is important for these immunocompromised patients to continue COVID-19 - necessary precautions like wearing masks, staying six feet away from others and avoiding crowds.

Source-Medindia